Blockbuster

How pharma and healthcare shifted strategies post-blockbuster drug success

How pharma and healthcare shifted strategies post-blockbuster drug success

Remedy Health Media's Mike Collins discusses ways pharma and healthcare companies have shifted their strategies in the years after the success of blockbuster drugs.

Five things for pharma marketers to know: Thursday, July 28, 2016

Five things for pharma marketers to know: Thursday, July 28, 2016

By

Vertex says Orkambi is on the blockbuster track; Advent and CVC reportedly made offers to buy inVentiv Health; the FDA approves Sanofi's Adlyxin

Five things for pharma marketers to know: Friday, March 25, 2016

Five things for pharma marketers to know: Friday, March 25, 2016

By

Gilead to pay Merck $200 million in HCV patent infringement suit; some patients aren't prescribed blood thinners; the FDA issues generic opioid guidance

Five things for pharma marketers to know: Wednesday, February 3, 2016

Five things for pharma marketers to know: Wednesday, February 3, 2016

By

Seven potential blockbusters set to launch in 2016; Amarin case may lead to 'misleading' marketing; Valeant, Turing raised prices to meet preset targets